TY - JOUR
T1 - Evaluating disease severity in chronic pain patients with and without fibromyalgia
T2 - A comparison of the symptom impact questionnaire and the polysymptomatic distress scale
AU - Friend, Ronald
AU - Bennett, Robert M.
N1 - Publisher Copyright:
© Copyright 2015 The Journal of Rheumatology. All rights reserved.
PY - 2015/12
Y1 - 2015/12
N2 - Objective. To compare the relative effectiveness of the Polysymptomatic Distress Scale (PSD) with the Symptom Impact Questionnaire (SIQR), the disease-neutral revision of the updated Fibromyalgia Impact Questionnaire (FIQR), in their ability to assess disease activity in patients with rheumatic disorders both with and without fibromyalgia (FM). Methods. The study included 321 patients from 8 clinical practices with some 16 different chronic pain disorders. Disease severity was assessed by the Medical Outcomes Study Short Form-36 (SF-36). Univariate analyses were used to assess the magnitude of PSD and SIQR correlations with SF-36 subscales. Hierarchical stepwise regression was used to evaluate the unique contribution of the PSD and SIQR to the SF-36. Random forest regression probed the relative importance of the SIQR and PSD components as predictors of SF-36. Results. The correlations with the SF-36 subscales were significantly higher for the SIQR (0.48 to 0.78) than the PSD (0.29 to 0.56; p < 0.001). Stepwise regression revealed that the SIQR was contributing additional unique variance on SF-36 subscales, which was not the case for the PSD. Random forest regression showed SIQR Function, Symptoms, and Global Impact subscales were more important predictors of SF-36 than the PSD. The single SIQR pain item contributed 55% of SF-36 pain variance compared to 23% with the 19-point WPI (the Widespread Pain Index component of PSD). Conclusion. The SIQR, the disease-neutral revision of the updated FIQ, has several important advantages over the PSD in the evaluation of disease severity in chronic pain disorders.
AB - Objective. To compare the relative effectiveness of the Polysymptomatic Distress Scale (PSD) with the Symptom Impact Questionnaire (SIQR), the disease-neutral revision of the updated Fibromyalgia Impact Questionnaire (FIQR), in their ability to assess disease activity in patients with rheumatic disorders both with and without fibromyalgia (FM). Methods. The study included 321 patients from 8 clinical practices with some 16 different chronic pain disorders. Disease severity was assessed by the Medical Outcomes Study Short Form-36 (SF-36). Univariate analyses were used to assess the magnitude of PSD and SIQR correlations with SF-36 subscales. Hierarchical stepwise regression was used to evaluate the unique contribution of the PSD and SIQR to the SF-36. Random forest regression probed the relative importance of the SIQR and PSD components as predictors of SF-36. Results. The correlations with the SF-36 subscales were significantly higher for the SIQR (0.48 to 0.78) than the PSD (0.29 to 0.56; p < 0.001). Stepwise regression revealed that the SIQR was contributing additional unique variance on SF-36 subscales, which was not the case for the PSD. Random forest regression showed SIQR Function, Symptoms, and Global Impact subscales were more important predictors of SF-36 than the PSD. The single SIQR pain item contributed 55% of SF-36 pain variance compared to 23% with the 19-point WPI (the Widespread Pain Index component of PSD). Conclusion. The SIQR, the disease-neutral revision of the updated FIQ, has several important advantages over the PSD in the evaluation of disease severity in chronic pain disorders.
KW - Fibromyalgia
KW - Fibromyalgia impact questionnaire
KW - Medical outcomes study short form-36
KW - Polysymptomatic distress
KW - Polysymptomatic distress scale
KW - Symptom impact questionnaire
UR - http://www.scopus.com/inward/record.url?scp=84948844688&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84948844688&partnerID=8YFLogxK
U2 - 10.3899/jrheum.150443
DO - 10.3899/jrheum.150443
M3 - Article
C2 - 26523027
AN - SCOPUS:84948844688
SN - 0315-162X
VL - 42
SP - 2404
EP - 2411
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 12
ER -